Trial
NCT03026166
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AbbVie
Collaborators
Bristol-Myers Squibb
Condition
Small Cell Lung Cancer
Intervention
Ipilimumab
Why stopped
Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of Cohort 2.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-17